Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trialElias Jabbour, Hagop Kantarjian, Wendy Stock et al.|Leukemia Research|2019Cited by 52
Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.Elias Jabbour, Hagop M. Kantarjian, Douglas Laird et al.|Journal of Clinical Oncology|2018Cited by 6